194 related articles for article (PubMed ID: 3921228)
1. HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
Coleman M; Pasmantier MW; Silver RT
Cancer; 1985 May; 55(10):2342-7. PubMed ID: 3921228
[TBL] [Abstract][Full Text] [Related]
2. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients.
Brower MS; Coleman M; Pasmantier MW; Silver RT; Mamaril AP; Quiguyan CC
Med Pediatr Oncol; 1984; 12(1):17-24. PubMed ID: 6321930
[TBL] [Abstract][Full Text] [Related]
4. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
Sessa C; Colombo N; Bolis G; Marsoni S; Mangioni C
Cancer Treat Rev; 1991 Mar; 18 Suppl A():37-46. PubMed ID: 1904308
[No Abstract] [Full Text] [Related]
7. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
8. Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
Richman CM; Podczaski E; Weiser PA; Herbst AL
Oncology; 1986; 43(1):12-7. PubMed ID: 3079898
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
Piver MS; Lele S; Barlow JJ
Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
[TBL] [Abstract][Full Text] [Related]
10. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
12. Cis-diamminedichloroplatinum (II): second line induction chemotherapy in advanced ovarian adenocarcinoma.
Piver MS; Barlow JJ; Lele SB; Malfetano JH; McPhee ME
J Surg Oncol; 1983 Dec; 24(4):329-31. PubMed ID: 6418977
[TBL] [Abstract][Full Text] [Related]
13. Alternating multiagent chemotherapy for advanced ovarian cancer.
Hernandez E; Rosenshein NB; Villar J; Dillon MB; Ettinger DS; Order SE
J Surg Oncol; 1983 Feb; 22(2):87-91. PubMed ID: 6296547
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB
J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434
[TBL] [Abstract][Full Text] [Related]
16. Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.
Bruckner HW; Cohen CJ; Bhardwaj S; Feuer E; Chesser MR; Holland JF
Eur J Cancer Clin Oncol; 1989 Sep; 25(9):1273-9. PubMed ID: 2509207
[TBL] [Abstract][Full Text] [Related]
17. Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.
Sessa C; Bolis G; Colombo N; D'Incalci M; Mermillod B; Valente I; Mangioni C
Cancer Chemother Pharmacol; 1985; 14(3):222-8. PubMed ID: 3922639
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
[TBL] [Abstract][Full Text] [Related]
19. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
Carlson JA; Day TG; Botts B; Masterson BJ
Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
[TBL] [Abstract][Full Text] [Related]
20. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
Bruckner HW; Cohen CJ; Feuer E; Holland JF
Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
